Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Castle Biosciences Inc.

    NASDAQ: CSTL · Real-Time Price · USD
    18.77
    -0.05 (-0.27%)
    At close: Jun 13, 2025, 3:59 PM
    18.99
    1.17%
    After-hours: Jun 13, 2025, 04:27 PM EDT

    Castle Biosciences Statistics

    Share Statistics

    Castle Biosciences has 28.87M shares outstanding. The number of shares has increased by 3.29% in one year.

    Shares Outstanding

    n/a
    		 28.87M

    Shares Change (YoY)

    n/a
    		 3.29%

    Shares Change (QoQ)

    n/a
    		 1.81%

    Owned by Institutions (%)

    n/a
    		 94.96%

    Shares Floating

    n/a
    		 27.94M

    Failed to Deliver (FTD) Shares

    n/a
    		 236

    FTD / Avg. Volume

    n/a
    		 0.05%

    Short Selling Information

    The latest short interest is 1.26M, so 4.36% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 1.26M

    Short % of Shares Out

    n/a
    		 4.36%

    Short % of Float

    n/a
    		 4.99%

    Short Ratio (days to cover)

    n/a
    		 3.41

    Valuation Ratios

    The PE ratio is 40.57 and the forward PE ratio is -9.32. Castle Biosciences's PEG ratio is -0.31.

    PE Ratio

    n/a
    		 40.57

    Forward PE

    n/a
    		 -9.32

    PS Ratio

    n/a
    		 2.23

    Forward PS

    n/a
    		 1.4

    PB Ratio

    n/a
    		 1.62

    P/FCF Ratio

    n/a
    		 20.26

    PEG Ratio

    n/a
    		 -0.31
    Financial Ratio History

    Enterprise Valuation

    Castle Biosciences has an Enterprise Value (EV) of 646.87M.

    EV / Sales

    n/a
    		 1.95

    EV / EBITDA

    n/a
    		 16.96

    EV / EBIT

    n/a
    		 9.97

    EV / FCF

    n/a
    		 17.7

    Financial Position

    The company has a current ratio of 7.29, with a Debt / Equity ratio of 0.06.

    Current Ratio

    n/a
    		 7.29

    Quick Ratio

    n/a
    		 7.13

    Debt / Equity

    n/a
    		 0.06

    Debt / EBITDA

    n/a
    		 0.69

    Debt / FCF

    n/a
    		 0.72

    Interest Coverage

    n/a
    		 15.03

    Financial Efficiency

    Return on Equity is 4% and Return on Invested Capital is 1.52%.

    Return on Equity

    n/a
    		 4%

    Return on Assets

    n/a
    		 3.43%

    Return on Invested Capital

    n/a
    		 1.52%

    Revenue Per Employee

    n/a
    		 $423,557.4

    Profits Per Employee

    n/a
    		 $23,271.68

    Employee Count

    n/a
    		 784

    Asset Turnover

    n/a
    		 0.63

    Inventory Turnover

    n/a
    		 7.4

    Taxes

    Income Tax

    n/a
    		 3.32M

    Effective Tax Rate

    n/a
    		 15.39%

    Stock Price Statistics

    The stock price has increased by -17.24% in the last 52 weeks. The beta is 1.04, so Castle Biosciences's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.04

    52-Week Price Change

    n/a
    		 -17.24%

    50-Day Moving Average

    n/a
    		 18.32

    200-Day Moving Average

    n/a
    		 25.56

    Relative Strength Index (RSI)

    n/a
    		 63.87

    Average Volume (20 Days)

    n/a
    		 432,241

    Income Statement

    In the last 12 months, Castle Biosciences had revenue of 332.07M and earned 18.25M in profits. Earnings per share was 0.66.

    Revenue

    n/a
    		 332.07M

    Gross Profit

    n/a
    		 271.86M

    Operating Income

    n/a
    		 8.67M

    Net Income

    n/a
    		 18.25M

    EBITDA

    n/a
    		 38.14M

    EBIT

    n/a
    		 22.14M

    Earnings Per Share (EPS)

    n/a
    		 0.66
    Full Income Statement

    Balance Sheet

    The company has 119.71M in cash and 26.34M in debt, giving a net cash position of 93.36M.

    Cash & Cash Equivalents

    n/a
    		 119.71M

    Total Debt

    n/a
    		 26.34M

    Net Cash

    n/a
    		 93.36M

    Retained Earnings

    n/a
    		 -200.13M

    Total Assets

    n/a
    		 501.71M

    Working Capital

    n/a
    		 312.11M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 64.87M and capital expenditures -28.33M, giving a free cash flow of 36.54M.

    Operating Cash Flow

    n/a
    		 64.87M

    Capital Expenditures

    n/a
    		 -28.33M

    Free Cash Flow

    n/a
    		 36.54M

    FCF Per Share

    n/a
    		 1.32
    Full Cash Flow Statement

    Margins

    Gross margin is 81.87%, with operating and profit margins of 2.61% and 5.49%.

    Gross Margin

    n/a
    		 81.87%

    Operating Margin

    n/a
    		 2.61%

    Pretax Margin

    n/a
    		 6.49%

    Profit Margin

    n/a
    		 5.49%

    EBITDA Margin

    n/a
    		 11.48%

    EBIT Margin

    n/a
    		 2.61%

    FCF Margin

    n/a
    		 11%

    Dividends & Yields

    CSTL does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 2.46%

    FCF Yield

    n/a
    		 4.94%
    Dividend Details

    Analyst Forecast

    The average price target for CSTL is $37, which is 97.1% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $37

    Price Target Difference

    n/a
    		 97.1%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 7
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 15.57

    Graham Upside

    n/a
    		 -17.05%

    Scores

    Altman Z-Score

    n/a
    		 5.55

    Piotroski F-Score

    n/a
    		 5

    Add to Watchlist